Study: Biomarkers could improve trials of Alzheimer's drugs

05/12/2009 | U.S. News & World Report

U.S. researchers found that measuring the levels of several biomarkers linked to Alzheimer's disease in the cerebrospinal fluid of patients with mild dementia might help predict the rate of their cognitive decline. The finding suggests that the biomarkers "might be useful as entry criteria for clinical trials of disease-modifying therapies for mild cognitive impairment and very mild dementia of the Alzheimer type," the researchers said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC